ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Immune surveillance interrupted: how cancer exploits trogocytosis.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trogocytosis is a contact-dependent process in which cells extract and internalize membrane fragments and associated molecules from neighboring cells. Although initially observed in immune cells, this phenomenon is now acknowledged as a deliberately orchestrated, meticulously regulated form of intercellular communication. Within the tumor microenvironment (TME), trogocytosis influences tumor recognition, modulates intracellular signaling pathways, and shapes the balance between immune activation and suppression. This review summarizes current insights into trogocytosis in the TME, focusing on its role across different adaptive and innate immune cells and how tumor cells exploit this process. This paper discusses how trogocytosis impacts antigen capture, regulates immune checkpoint expression, and modifies the function of effector cells, thereby reshaping antitumor immunity. By integrating mechanistic findings and emerging therapeutic concepts, this review highlights trogocytosis as both a driver of immune dysfunction in cancer and a potential target for strategies aimed at improving immunotherapy outcomes.
Indexed as
Identifiers
42322558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.